Introduction
• Cost-effectiveness models help decision-makers to ensure the most efficient use of scarce resources.
• Where treatments affect mortality, such models use estimates of timeto-event for outcomes such as death to estimate costs and health outcomes.
• In order to obtain unbiased estimates of incremental lifetime costs and health outcomes, it is often necessary to extrapolate -based on parametric survival analysis -beyond the time horizon of observed events.
• Although some argue that the observed survival curve as represented by the Kaplan-Meier (KM) curve provides the "best" estimate of survival, parametric survival analysis may make more efficient use of observed data than KM methods that include numerous "implicit" parameters that are not explicitly estimated.
o Figure 2 shows the potential uncertainty in a KM estimate of survival.
• However, although parametric models may be more efficient, estimates of cost-effectiveness may be sensitive to the choice of functional form [1] [2] .
• The selection of the "preferred" functional form may be highly uncertain, particularly when modelling small numbers of patients and events.
• Some recommendations for selection of functional form and addressing associated structural uncertainty have been recently published [3] [4] .
o These focus on identifying a single "preferred" functional form and incorporating structural uncertainty by comparing alternative plausible models.
• Bootstrap model averaging (BOOT) uses a weighted average of results from the set of candidate models rather than the result from a single model selected from the set of candidate models.
o By providing a single model estimate which incorporates uncertainty in model selection, BOOT helps to address the problem of bias and underestimation of uncertainty that arises when a number of models are investigated, but only the ''best'' model is reported and all subsequent inference is based on this model.
o BOOT is simpler to implement than a fully Bayesian MC-cubed approach 5 .
Objectives
• To explore the use of BOOT when estimating survival curves for costeffectiveness analysis using an illustrative "real life" example.
Methods

Real life example
• A set of four clinical trials in advanced soft tissue sarcoma [6] [7] [8] [9] were identified from a published systematic review.
o Two studies were comparative randomised controlled trials, and two were non-comparative single arm studies.
o None of the studies contained a common comparator; hence the network of study comparisons was disconnected.
o All studies reported KM curves for overall survival (OS) (Figure 1 ).
• The individual patient data (IPD) for all studies were estimated using a published algorithm.
o The published KM curves were digitised using TechDig® software to estimate the survival probability at a range of time points. o An algorithm 10 was then used to estimate the IPD, generating a timeto-event and a censoring variable for each patient.
Fitting and selection of "preferred" parametric survival models
• Seven parametric functional forms (exponential, Weibull, Gompertz, lognormal, log-logistic, gamma and Generalised gamma) were considered.
• For comparative studies, a joint survival model was fitted using a treatment dummy covariable.
• The "preferred" model was defined as the one with the lowest Bayesian information criterion (BIC):
where;
o ln(L) is the log-likelihood o k is the number of model parameters o n is the number of patients
• The BIC measure of fit was used as it penalises additional parameters more heavily than the Akaike information criterion (AIC) for larger samples
o BIC penalty term; kln(n) o AIC penalty term; 2k
• The preferred functional form was independently selected for each study hence functional form could differ across studies.
• A bootstrap analysis was conducted to estimate the uncertainty in the selection of functional form for each study.
o 1,000 bootstrapped samples of the IPD for each study were taken.
o Figure 2 demonstrates the uncertainty in the KM estimate of survival based on 10 bootstrapped samples for Study 2.
o Uncertainty in the selection of functional form was estimated as the proportion of bootstrapped samples in which each functional form had the lowest BIC.
• The estimated probabilities that each functional form was preferred formed the weights for the BOOT estimate.
o These were applied to the mean survival estimates using each functional form (applied to the original data set) to obtain a weighted average estimate of mean survival for each treatment (BOOT estimate).
o The standard error for the BOOT estimate was calculated as the standard deviation of the BOOT means across the bootstrapped samples.
Results
• The preferred functional form varied across studies (Table 1) .
o Different functional forms (Gompertz, gamma, Generalised gamma, log-logistic) were selected for each study. Bold underlined data are for preferred functional form
• The bootstrap analyses indicated considerable uncertainty regarding the choice of functional form (Table 2) .
o The bootstrap estimate of the probability that the preferred functional form (selected based on the original dataset) had the lowest BIC varied from 16% to 71% across studies.
• The choice of functional form influenced the mean survival predictions (Table 3) .
o The within-study variation in mean survival between functional forms ranged from 0.3 months to 2.4 months (compared to a maximum mean survival of 13.9 months). Bold underlined data are for preferred functional form
• The uncertainty in the selection of the preferred functional form is illustrated in Figure 3 . The KM curves are shown for 12 bootstrapped samples for Study 3 alongside the preferred parametric extrapolation for each sample. Bold underlined data are for preferred functional form
• The standard error of the mean survival estimate was lower for the weighted BOOT estimate than when a single preferred functional form was selected (Table 4) . 
Discussion
• These results demonstrate that mean survival estimates are sensitive to the choice of functional form.
• Choice of functional form was found to be uncertain, implying uncertainty in estimates of mean survival and cost-effectiveness.
• The BOOT estimator avoids the need to select a single functional form and reduced the variance in estimates of mean survival.
o However, such an analysis would be computationally onerous.
Limitations
• In this analysis we have focused on BIC as a measure of model fit, however there are other measures and wider criteria that might be considered.
o BIC does not incorporate the clinical plausibility of any extrapolation. o Each bootstrap sample would itself be bootstrapped to estimate a set of model weights. These would be peculiar to the individual bootstrap sample.
o In the current analysis the weights are estimated from the bootstrapped analysis of the original data set.
Conclusions
• The process for conducting parametric survival analysis for costeffectiveness analysis has been widely discussed, and recommendations for identifying the most appropriate model and incorporating structural uncertainty have been presented in the literature.
• In contrast to the use of a single preferred functional form, the use of BOOT to estimate mean survival can reduce the variance in mean survival estimates, and avoids the need for selecting a single functional form for a parametric survival model.
• Given the considerable uncertainty in selecting a functional form and the influence of this process on mean survival estimates, BOOT could act as a useful method for addressing uncertainty in functional form selection and hence in cost-effectiveness analyses. 
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